145 related articles for article (PubMed ID: 34054700)
21. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
22. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials.
Wang ZY; Shi SY; Li SJ; Chen F; Chen H; Lin HZ; Lin JM
Pain Med; 2015 Jul; 16(7):1373-85. PubMed ID: 26176791
[TBL] [Abstract][Full Text] [Related]
24. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
25. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
26. An individual patient analysis of the efficacy of using GPi-DBS to treat Huntington's disease.
Yin Z; Bai Y; Zhang H; Liu H; Hu W; Meng F; Yang A; Zhang J
Brain Stimul; 2020; 13(6):1722-1731. PubMed ID: 33038596
[TBL] [Abstract][Full Text] [Related]
27. Interrater Reliability of the Unified Huntington's Disease Rating Scale-Total Motor Score Certification.
Winder JY; Roos RAC; Burgunder JM; Marinus J; Reilmann R
Mov Disord Clin Pract; 2018; 5(3):290-295. PubMed ID: 30363437
[TBL] [Abstract][Full Text] [Related]
28. Motor outcome measures in Huntington disease clinical trials.
Reilmann R; Schubert R
Handb Clin Neurol; 2017; 144():209-225. PubMed ID: 28947119
[TBL] [Abstract][Full Text] [Related]
29. Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats.
Waters S; Ponten H; Klamer D; Waters N
J Huntingtons Dis; 2014; 3(3):285-98. PubMed ID: 25300332
[TBL] [Abstract][Full Text] [Related]
30. Anti-inflammatory medications for obstructive sleep apnoea in children.
Kuhle S; Hoffmann DU; Mitra S; Urschitz MS
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD007074. PubMed ID: 31978261
[TBL] [Abstract][Full Text] [Related]
31. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
32. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Ferreira JJ; Rosser A; Craufurd D; Squitieri F; Mallard N; Landwehrmeyer B
Mov Disord; 2015 Sep; 30(10):1426-9. PubMed ID: 26175332
[TBL] [Abstract][Full Text] [Related]
33. One-year safety and tolerability profile of pridopidine in patients with Huntington disease.
Squitieri F; Landwehrmeyer B; Reilmann R; Rosser A; de Yebenes JG; Prang A; Ivkovic J; Bright J; Rembratt A
Neurology; 2013 Mar; 80(12):1086-94. PubMed ID: 23446684
[TBL] [Abstract][Full Text] [Related]
34. Assessment Scales for Patients with Advanced Huntington's Disease: Comparison of the UHDRS and UHDRS-FAP.
Winder JY; Achterberg WP; Marinus J; Gardiner SL; Roos RAC
Mov Disord Clin Pract; 2018; 5(5):527-533. PubMed ID: 30515443
[TBL] [Abstract][Full Text] [Related]
35. Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis.
Van de Roovaart HJ; Nguyen N; Veenstra TD
Pharmaceuticals (Basel); 2023 Oct; 16(11):. PubMed ID: 38004378
[TBL] [Abstract][Full Text] [Related]
36. Non-Invasive Neuromodulation Methods to Alleviate Symptoms of Huntington's Disease: A Systematic Review of the Literature.
Jose L; Martins LB; Cordeiro TM; Lee K; Diaz AP; Ahn H; Teixeira AL
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902788
[TBL] [Abstract][Full Text] [Related]
37. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
Brownstein MJ; Simon NG; Long JD; Yankey J; Maibach HT; Cudkowicz M; Coffey C; Conwit RA; Lungu C; Anderson KE; Hersch SM; Ecklund DJ; Damiano EM; Itzkowitz DE; Lu S; Chase MK; Shefner JM; McGarry A; Thornell B; Gladden C; Costigan M; O'Suilleabhain P; Marshall FJ; Chesire AM; Deritis P; Adams JL; Hedera P; Lowen K; Rosas HD; Hiller AL; Quinn J; Keith K; Duker AP; Gruenwald C; Molloy A; Jacob C; Factor S; Sperin E; Bega D; Brown ZR; Seeberger LC; Sung VW; Benge M; Kostyk SK; Daley AM; Perlman S; Suski V; Conlon P; Barrett MJ; Lowenhaupt S; Quigg M; Perlmutter JS; Wright BA; Most E; Schwartz GJ; Lamb J; Chuang RS; Singer C; Marder K; Moran JA; Singleton JR; Zorn M; Wall PV; Dubinsky RM; Gray C; Drazinic C
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33207828
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 as a marker of Huntington's disease progression: Systematic review and meta-analysis.
Eide S; Misztal M; Feng ZP
Brain Behav Immun Health; 2023 Jul; 30():100635. PubMed ID: 37215308
[TBL] [Abstract][Full Text] [Related]
39. Time-Restricted Ketogenic Diet in Huntington's Disease: A Case Study.
Phillips MCL; McManus EJ; Brinkhuis M; Romero-Ferrando B
Front Behav Neurosci; 2022; 16():931636. PubMed ID: 35967897
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
